Joseph R. Mikhael

Dec 3, 2024 | cancernetwork.com | Joseph R. Mikhael

December 3, 2024Panelist discusses the current acceleration of new therapies for multiple myeloma. In the future, oncologists will be able to use CAR T and bispecific therapies more efficiently, and they will also have new tools including new CAR T therapies and bispecifics that will require less manufacturing time, have fewer AEs, and be more effective regarding the targeted disease.

Nov 27, 2024 | cancernetwork.com | Joseph R. Mikhael

November 27, 2024Panelist discusses how every drug oncologists use comes with adverse events (AEs), and with bispecifics they are seeing a similar AE profile to that seen in CAR T-cell therapy. There are 3 major AEs: cytokine release syndrome, neurological toxicity, and infections. To manage AEs, oncologists are now monitoring patients more intensely as well as engaging with the patient’s family to provide updates on the status of the patient.

May 29, 2023 | nature.com | Rahul Banerjee |Joseph R. Mikhael

In their 1980s classic “Should I stay or should I go,” the Clash rock band ponders whether to continue an imperfect relationship or to move on. Autologous stem cell transplantation (ASCT) for multiple myeloma (MM), another product largely of the 1980s [1], sometimes poses the same dilemma decades later for patients with potentially insufficient responses to pre-ASCT induction therapy.

Mar 14, 2023 | nature.com | Paul Richardson |Aurore Perrot |Joseph R. Mikhael |Thomas Martin |Meral Beksac |Ivan Spicka | +2 more

AbstractThe International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone) and IKEMA (isatuximab–carfilzomib–dexamethasone vs.